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Abstract
We addressed growth of biliary atresia (BA) patients living with native livers between ages 0–6 and effects of post-surgical
corticosteroid treatment on growth. Growth charts of 28 BA patients born in Finland between 1987 and 2017were retrospectively
evaluated. Dosage and length of corticosteroid treatment and hydrocortisone substitution were reviewed. At birth, BA patients
were shorter (median height − 0.6 (interquartile range (IQR) − 1.3 to − 0.1) SDS, n = 28, P < 0.001) than general population.
Height remained stable during early childhood (median height − 0.6 (IQR − 1.4 to 0.1) SDS for girls and − 0.4 (IQR − 1.6 to 0.2)
SDS for boys at 6 years of age). Patients were of normal height adjusted weight at 6 years with a median age and sex-adjusted
body mass index (ISO-BMI) of 20.9 (IQR 19.3 to 25.0) for girls and 22.1 (IQR 20.7 to 25.6) for boys. Higher (≥ 50 mg/kg)
cumulative post-portoenterostomy prednisolone dosage resulted in 0.18 SDS lower height per treatment week (β − 0.18, SE 0.04,
P < 0.001) compared to lower dosage (< 50 mg/kg).
Conclusion: BA patients grow normally during early childhood. As high postoperative corticosteroid dosage has a short-term
negative effect on height, very high dosages should be avoided.
What Is Known:
• Growth of biliary atresia patients has mostly been shown to be within normal limits
• Corticosteroids may decrease growth rate
What Is New:
• Biliary atresia patients surviving with their native livers are shorter than general population and their mid-parental target height at birth
• A high (> 50 mg/kg) cumulative prednisolone dosage has a negative transitory impact on height gain after portoenterostomy
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Abbreviations
BA Biliary atresia
BASM Biliary atresia splenic malformation
COJ Clearance of jaundice
DW% Weight-for-length
IQR Interquartile range
ISO-BMI Age- and sex-adjusted body mass index
LT Liver transplantation
MPH Mid-parental target height
PE Portoenterostomy
SDS Standard deviation scores
Introduction
Biliary atresia (BA) is an idiopathic fibro-obstructive
cholangiopathy manifesting in infancy [20]. The incidence
of BA is varied between 1:8000 and 1:10000 reported in
Asia to 1:17000–1:20000 in Northern Europe [26–28].
Untreated, obstruction of intra- and extrahepatic biliary tracks
leads to fibrosis, liver failure, and death in the first 2 years. The
current first-line surgical treatment is portoenterostomy (PE).
Provided PE restores adequate bile flow, between 23% and
44% of patients survive with native livers until the age of 20
[10, 29, 41]. Liver transplantation (LT) remains a second-line
treatment option and BA is the most common indication for
childhood LTs [20, 30].
Following PE, commonly used adjunct postoperative man-
agement includes ursodeoxycholic acid, prophylactic antibi-
otic treatment, and nutritional management [11, 47, 49].
Corticosteroids may improve clearance of jaundice (COJ)
rates but potential side effects include an elevated risk for
infections, gastrointestinal bleeding, osteoporosis, and poor
growth [5, 7, 9]. Growth patterns of patients surviving with
their native livers have rarely been reported on, and data on the
effect post-PE corticosteroids have on growth are very limited
[1, 5, 12, 34]. The aim of this study was to characterize growth
of BA patients surviving with their native livers between the
ages 0–6. Furthermore, we measured the effect of post-PE
corticosteroids on growth.
Methods
Patients
We included term BA patients born in Finland between
1987 and 2017 who had normalized their bilirubin <
20 μmol/l after PE, were at least 4 months old, and were
living with their native livers as of 31st of December
2017. Data on gestational age, birth height, and weight,
associated congenital malformations, BA-type [36], age at
surgery, serial height and weight measurements,
corticosteroid treatment, and subsequent hydrocortisone
substitution were retrospectively collected from medical
records. Term infant was defined as weight at or above
2500 g and gestational age between 37 and 42 weeks at
birth. Biliary atresia splenic malformation (BASM) was
defined as presence of poly- or asplenia [8]. Clearance
of jaundice was defined as serum total bilirubin <
20 μmol/L.
Growth data
Height and weight at birth as well as at 3, 6, 9, 12, 15, 18,
21, and 24 months and at yearly intervals between 2 and
20 years of age were retrospectively collected from med-
ical records. Height and weight at PE and at 1, 2, 3, 4, 5,
6, 9, 12, 15, 18, 21, and 24 months after PE were also
retrieved from medical records. For the first year, mea-
surements performed within a ± 4-week period of the ex-
act time point were accepted but for growth data after
portoenterostomy, for the first 12 months, the nearest
available measurement was accepted if it was within a ±
2-week period of the exact time point. After 12 months,
measurements within a ± 6-week period of the except time
point were accepted.
Height was analyzed as standard deviation scores
(SDS) from the mean of age- and sex-adjusted national
values [39]. Normal height was defined as height SDS
between − 2.0 and 2.0. Mid-parental target height SDS
were calculated according to the equations: 0.791 × mean
parental height SDS − 0.147 for girls and 0.886 × mean
parental height SDS – 0.071 for boys [40]. Between birth
and 2 years of age, relative weight was analyzed as
weight-for-length, i.e., the percentage deviation of weight
from the median weight for length and sex (DW%) [39,
44]. After the age of 2, relative weight was analyzed with
age- and sex-adjusted body mass index (ISO-BMI) [39].
During the first 2 years, underweight was defined as
DW% < − 20.0, normal weight as DW% between − 20.0
and + 20.0 and overweight as DW% > 20.0 [39, 44]. For
relative weight between ages 2–6, the following ISO-BMI
categories were used: underweight (< 17 kg/m2), normal
weight (17–25 kg/m2), overweight (> 25 kg/ m2), and
obesity (> 30 kg/m2) [39]. While calculating changes in
relative weight after portoenterostomy, relative weight
was analyzed as weight-for-length for consistency. The
most recently published national reference data was used
for calculation of SDS of weight and length [39].
Corticosteroid treatment
Cumulative dosage of glucocorticoid treatment after PE,
the length and dosage of subsequent hydrocortisone sub-
stitution regimen, and measured serum cortisol values
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after corticosteroid treatment were reviewed from patient
records. Corticosteroid dosage was converted to equivalents
of prednisolone, and total cumulative dosage of prednisolone
(mg) per weight (kg) was calculated. In converting, 5 mg of
prednisolone was considered to be equivalent to 5 mg of pred-
nisone, 20 mg of hydrocortisone, 670 μg of dexamethasone,
and 4 mg of methylprednisolone [31]. A high total predniso-
lone dosage was considered to be ≥50 mg/kg [9]. All possible
glucocorticoid usages related or unrelated to BA after the ini-
tial treatment period were recorded. The relationship of cumu-
lative glucocorticoid dosage to changes in relative height and
weight 2 years after PE were analyzed. While analyzing the
impact corticosteroids had on growth, possible impact was
hypothesized to start at the beginning of medication and con-
tinue until 24 months. Prior to national centralization of BA
treatment in 2005 [26], varied postoperative management pro-
tocols were used with a median cumulative postsurgical cor-
ticosteroid dosage corresponding to 50 mg/kg (IQR 26 to 62)
of prednisolone. After centralization, adjuvant corticosteroid
therapy after PE has been used [22]. Between 2005 and 2014,
corticosteroid therapy with oral dexamethasone corresponded
to cumulative dosage of 45 mg/kg of prednisolone; since
2015, the dosage has corresponded to 75 mg/kg of
prednisolone.
Statistical methods
Values are expressed as medians with interquartile range
(IQR) unless otherwise stated. Wilcoxon signed-rank test
was used to compare matched groups. Growth of patients
was modeled using linear mixed models [4]. Models in-
cluded random effect of participants on all time terms.
Analyses were carried out in R version 3.4.1 using pack-
ages lme4 and lmerTest [25, 38]. Degrees of freedom
were estimated using Satterthwaite approximations. The
statistically significant level was set to P < 0.05.
Results
Patient characteristics
During the study period, 96 patients were diagnosed with
BA in Finland. Of these, 30 patients had died, 28 were
alive with a liver transplant (median age at transplantation
1.45 (0.84 to 2.51) years), 3 were born preterm and 1 had
a birthweight < 2500 g. Thus, 34 patients fulfilled the
initial inclusion criteria. Six patients were excluded as
follows: two because of missing height measurements at
birth and four because both parents were non-European.
As shown in Table 1, median gestational age was
39 weeks. Most patients were diagnosed with BA type 3
and PE was performed at median age 63 days. Median
follow-up age was 8.1 years and patients had well-
preserved liver function.
Height gain between 0 and 6 years
At birth, BA patients were shorter (median height − 0.6 (− 1.3
to − 0.1) SDS for all patients, n = 28, P < 0.001) than the gen-
eral population. Median height SDS of patients with mid-
parental target height (MPH) data (n = 20) was − 0.2 (− 1.2
to 0.2), which was 0.1 SDS below their median MPH of −
0.1 (− 0.4 to 0.4) SDS (median difference 0.3, n = 20,
P < 0.05).
Growth rate appeared to slow down during the first
3 months, as median height for all patients at 3 months was
− 1.70 (− 2.3 to − 1.1) SDS. Change in growth rate was more
drastic for boys (n = 13); their median SDS changed from −
0.6 (− 1.5 to − 0.1) at birth to − 1.8 (− 2.5 to − 0.8) at 3 months
while girls’ (n = 15) median SDS changed from − 0.7 (− 0.7 to
0.4) SDS to − 1.4 (− 1.8 to − 1.1) SDS (Fig. 1). At 6 months,
boys’ growth rate accelerated as median height for all patients
was − 1.2 (− 2.2 to − 0.7) SDS, − 1.2 (− 2.1 to − 0.5) SDS for
boys and − 1.3 (− 2.3 to − 0.7) SDS for girls. Between 6 and
24months, growth rate was stable (Fig. 1). At 2 years, patients
remained shorter (median height for all patients − 0.8 (− 1.2 to
− 0.1) SDS) than the general population. At 2 years, 11/13
(85%) of the patients had height SDS below MPH (median
difference = 0.8, n = 13, P < 0.05).
Height gain was stable between ages 2–6. Girls’ height was
unaltered with median height at − 0.6 (− 1.2 to − 0.1 and − 1.4
to 0.1 at 2 and 6 years, respectively) SDS while boys’median
height changed from − 0.9 (− 1.3 to 0.0) SDS to − 0.4 (− 1.6 to
0.2) SDS.
Weight gain between 0 and 6 years
At birth, patients were of normal weight with median 0.0 (−
5.0 to 5.5) DW% for all, 2.0 (− 5.0 to 6.0) DW% for girls and
0.0 (− 6.0 to 4.5) DW% for boys. During the first 2 years, both
genders remained of normal weight with median of 2.5 (− 1.0
to 10.5) DW% for all, − 1.0 (− 3.5 to 4.0) DW% for girls and
8.0 (2.5 to 17.5) DW% for boys at 2 years of age (Fig. 1).
When analyzing with ISO-BMI, at 2 years, overall me-
dian ISO-BMI was 24.1 (20.5 to 28.8), i.e., on the upper
margin of normal range. There was a distinct difference
between genders; girls were of normal weight with medi-
an of 21.1 (19.7 to 23.3) ISO-BMI while boys were over-
weight with a median of 25.9 (24.1 to 32.3) ISO-BMI
(Fig. 2). Girls’ weight remained constant between ages
2–6 years with a median of 20.9 (19.3 to 25.0) ISO-
BMI at 6 years. Boys’ weight decreased slightly with −
1.06 (β − 1.06, SE 0.33, P < 0.05) ISO-BMI yearly with
median ISO-BMI at 22.1 (20.7 to 25.6) at 6 years (Fig. 2).
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Postoperative corticosteroid treatment and growth
Complete data for postsurgical corticosteroid treatment was
available for 24 out of 28 patients, including 3 patients not
treated with corticosteroids. Corticosteroid treatment started at
median 5 (range 4–17) days after PE at median age of 70
(range 18–167) days. The median length of corticosteroid-
treatment was 18.5 (range 0–49) days. Sixteen patients re-
ceived hydrocortisone substitution. Total median cumulative
corticosteroid dosage was 277.6 (186.6 to 374.2) mg and 63.6
(47.7 to 74.6) mg/kg of prednisolone excluding hydrocorti-
sone substitution. Median hydrocortisone dosage during the
first 30 days of substitution was 8.2 (range 5.0–21.2) mg/m2/
day and median treatment length was 37 (range 12–133) days.
Serum cortisol values were suppressed after glucocorticoid
treatment in 12 out of 19 patients (63%)withmeasured values.
At PE (median age 65 (IQR 26 to 90) days), patients were
1.51 (β − 1.51, SE 0.19, P < 0.001) SDS shorter than the
general population. A growth model for cumulative prednis-
olone dosage showed 0.16 (β − 0.16, SE 0.04, P < 0.001) SDS
decrease in height for each 100 mg of prednisolone. In a
mixed model, there was 0.18 (β − 0.18, SE 0.04, P < 0.001)
SDS decrease in height for each 100 mg of prednisolone while
hydrocortisone substitution caused faint 0.07 (β 0.07, SE 0.02,
P < 0.05) SDS increase in height per treatment week. A
weight-adjusted dosage model showed negative effect on
height with 0.25 (β − 0.25, SE 0.05, P < 0.001) SDS decrease
for each 100 mg of prednisolone per treatment week. In a
mixed model, weight-adjusted dosage of prednisolone dem-
onstrated 0.27 (β − 0.27, SE 0.05, P < 0.001) SDS decrease
for each 100 mg of prednisolone per treatment week while
hydrocortisone substitution caused 0.07 (β 0.07, SE 0.02,
P < 0.01) SDS increase in height per week. A higher total
corticosteroid dosage (> 50 mg/kg) resulted in 0.18 (β −
0.18, SE 0.04, P < 0.001) SDS lower height per treatment
week compared to lower dosage. The effect remained in a
Table 1 Patient characteristics
All patients Patients with glucocorticoid data
Number of patients 28 24
Gestational age, wk, median (IQR) 39 (38–40) 39 (38–40)
Females, n (%) 15 (54) 12 (50)
Birth weight, median (IQR)
kg 3.340 (3.081–3.669) 3.363 (3.081–3.669)
% 0.0 (− 5.0–5.5) 0.0 (− 6.5–5.5)
Birth height, median (IQR)
cm 50.0 (48.6–51.0) 50.0 (49.0–51.0)
SD − 0.6 (− 2.2–(− 0.1)) − 0.6 (− 1.0–0.3)
Biliary atresia type n (%)
1 0 (0.0) 0 (0.0)
2 2 (7.1) 0 (0.0)
3 26 (92.9) 24 (100)
Biliary atresia splenic malformation, n (%) 3 (11) 3 (13)
Any other anomaly, n (%) 10 (36) 8 (33)
Age at portoenterostomy (PE), days, median (IQR) 63 (24–83) 65 (26–90)
Time to clearance of jaundice, months, median (IQR) 2 (1–3) 2.5 (1–3.8)
Diagnosed with portal hypertension, n (%) 12 (43) 12 (50)
Age at last follow-up, years, median (range) 8.1 (0.3–19.7) 7.8 (0.3–19.7)
Biochemical markers at last follow-up:
Bilirubin, μmol/L, median (IQR) 8.5 (7–14) 8.5 (5.5–14.8)
Conjugated bilirubin, μmol/L, median (IQR) 4 (3–7) 4.0 (3–7.8)
Alanine aminotransferase, U/L, median (IQR) 40 (19–76) 55 (27–77)
Aspartate aminotransferase, U/L, median (IQR) 54 (34–90) 57 (42–100)
Glutamyl transferase, U/L, median (IQR) 48 (21–100) 65 (27–105)
Albumin, g/L, median (IQR) 38 (32–40) 37 (32–40)
Thromboplastin time %, median (IQR) 87 (73–100) 87 (73–105)
Thrombocytes, × 109/L, median (IQR) 174 (79–268) 155 (71–268)
IQR interquartile range, PE = portoenterostomy. Biliary atresia types as defined by Ohi et al. [18], portal hypertension as defined by Shneider et al. [42]
344 Eur J Pediatr (2019) 178:341–349
a. b. c.
d. e. f.
Fig. 1 Growth of BA patients during first 2 years, postnatal age, 3-month
intervals. a Height SDS of all patients. b Height SDS of girls. c Height
SDS of boys. d Weight-for-length (DW%) of all patients. e Weight-for-
length (DW%) of girls. f Weight-for-length of boys (DW%). Gray area
between dashed lines: normal weight with DW%.Data are presentedwith
median and interquartile range (percentile 25–75). SDS, standard devia-
tion scores from the mean of age- and sex-adjusted value; DW%, per-
centage deviation of weight from median weight for length and sex;
MPH, mid-parental target height
Fig. 2 Growth of BA patients between 2 to 6 years with yearly intervals.
a Height SDS of all patients. b Height SDS of girls. c Height SDS of
boys. d Weight ISO-BMI of all patients. e Weight ISO-BMI of girls. f.
Weight ISO-BMI of boys. Gray area between dashed lines: normal
weight with ISO-BMI. Data are presented with median and interquartile
range (percentile 25–75). SDS, standard deviation scores from the mean
of age- and sex-adjusted value; ISO-BMI, age- and sex-adjusted body
mass index
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model including higher corticosteroid dosage (β − 0.21, SE
0.04, P < 0.001) and hydrocortisone substitution (β − 0.05,
SE 0.02, P < 0.01). Suppression of cortisol production caused
1.37 (β − 1.37, SE 0.55, P < 0.05) SDS decrease per week in
height compared to unsuppressed patients (Table 2).
Patients were of normal weight with − 0.44 (β − 0.44, SE
1.53, P 0.776) DW% at time of portoenterostomy. A growth
model for total cumulative prednisolone showed no effect on
weight, nor did a growth model combining cumulative prednis-
olone and hydrocortisone substitution (Table 2). A growth
model with weight-adjusted corticosteroid dosage showed no
effect of prednisolone on weight nor did a model combining
weight-adjusted dosage and hydrocortisone substitution
(Table 2). A higher total corticosteroid dosage caused 1.12 (β
1.12, SE 0.36, P < 0.01) DW% increase in weight per treatment
week compared to lower dosage, the effect remained (β 0.87,
SE 0.38, P < 0.05) in a mixed model including hydrocortisone
substitution (β 0.32, SE 0.15, P < 0.05). Suppression of cortisol
production had no effect (Table 2).
Discussion
We describe growth patterns of term BA patients living with
native livers from birth until early childhood. We found that
they are shorter than general population and their mid-parental
target height at birth. Their height gain remains constant dur-
ing infancy and early childhood. BA patients were born of
normal weight and remained of normal weight during first
2 years. Girls remained of normal weight between 2 and
6 years whereas boys’ weight, while analyzed with ISO-
BMI, slimmed down from overweight to normal weight. A
high cumulative corticosteroid treatment dosage had a marked
temporary negative impact on height gain.
Table 2 Linear mixed models’ results for height and weight for
different parameters. The estimates are for either changes in
standardized height (SD) or ISO-BMI.Models for (1.) time only, (2.) time
and cumulative prednisolone, (3a.) time and weight-adjusted
prednisolone, (4a.) time and high prednisolone dosage, and (5.) time
and cortisol suppression. The (b) models extended the (a) models with
hydrocortisone substitution
Models for heighta: Parameter Estimate, β Standard error, SE P
1. Intercept − 1.51 0.19 < 0.001
Time, 1 month 0.05 0.01 < 0.001
2 a. Cumulative prednisolone per 100 mg − 0.16 0.04 < 0.001
b. Cumulative prednisolone per 100 mg − 0.18 0.04 < 0.001
Hydrocortisone substitution per week 0.07 0.02 0.007
3 a. Weight-adjusted prednisolone per
100 mg per week
− 0.25 0.05 < 0.001
b. Weight-adjusted prednisolone per
100 mg per week
− 0.27 0.05 < 0.001
Hydrocortisone substitution per week 0.07 0.02 0.004
4 a. High dosage per week − 0.18 0.04 < 0.001
b. High dosage per week − 0.21 0.04 < 0.001
Hydrocortisone substitution per week − 0.05 0.02 0.006
5. Cortisol suppression per week − 1.37 0.55 0.014
Models for weighta:
1. Intercept − 0.44 1.53 0.776
Time, 1 month 0.31 0.11 0.011
2 a. Cumulative prednisolone per 100 mg 0.58 0.40 0.144
b. Cumulative prednisolone per 100 mg 0.47 0.42 0.263
Hydrocortisone substitution per week 0.15 0.17 0.384
3 a. Weight-adjusted prednisolone per
100 mg per week
0.32 0.47 0.496
b. Weight-adjusted prednisolone per
100 mg per week
0.16 0.49 0.751
Hydrocortisone substitution per week 0.19 0.17 0.259
4 a. High dosage per week 1.12 0.36 0.002
b. High dosage per week 0.87 0.38 0.024
Hydrocortisone substitution per week 0.32 0.15 0.033
5. Cortisol suppression per weeks 2.43 5.15 0.638
aAll models adjusted for follow-up time, except for the first (1.) time only univariate model
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Results on weight varied at 2 years of age depending
whether relative weight was analyzed with DW% or ISO-
BMI; when analyzed with DW%, both girls and boys were
of normal weight whereas boys were overweight when ana-
lyzed with ISO-BMI. This discrepancy likely stems from the
fact that there is no known correlation of DW% and ISO-BMI
between ages 0 to 2. Single USA-based study comprising
4348 children found poor correlation between weight-for-
height and BMI-for-age between ages 2–5. In line with our
findings, high percentage (63.4%) of children had lower
weight-for-height percentile than BMI-for-age percentile at
the same age [16].
Patients in our study are shorter than general population
and their mid-parental target height at birth. BA associated
with cytomegalovirus infection has been described to have
worse clinical outcome with increased mortality [50], al-
though a previous study from Sweden yielded equal clinical
results independent of cytomegalovirus status [15].
Symptomatic congenital cytomegalovirus infection may man-
ifest as stunted growth especially affecting birth weight, how-
ever, the vast majority of children with congenital cytomega-
lovirus infection are asymptomatic [6, 13, 33]. As none of the
patients in our study were diagnosed with cytomegalovirus
infection, it is unlikely that this virus caused the diminished
birth height.
Published data assessing growth of nonjaundiced children
with BA living with native livers in early childhood are sparse.
Sokol et al. [43] found depressed height and weight z-scores
but normal weight-for-height z-scores for 32 BA patients in
early childhood. However, as 21 out of 32 patients in their
cohort had signs of cirrhosis although patients were clinically
stable, it is likely that our study group consists of healthier
patients. Karrer et al. [23] reported normal height scores for
the majority of 30 patients surviving at least 10 years after
portoenterostomy but their results also included transplanted
patients. Thirty-five out of 38 nonjaundiced BA patients sur-
viving with native livers at least 10 years were reported to
have normal growth by Valayer [46]. Hadzić et al. [19] found
normal height and weight z-scores at follow-up in 28 BA
patients living with native livers, these patients were also con-
siderable older adolescents compared to our cohort (median
age 13.4 (range 10.2–22.2) years vs 8.1 (range 0.3–19.7) years
in our cohort). Ng et al. [34] reported normal median height
and weight z-scores for 219 BA patients (median age 9.7
(range 5.1–17.9)) living with native livers at least 5 years after
portoenterostomy. Similarly to our findings, Arvay et al. [2]
described decreased height-for-age and normal weight-for-age
in a group of 10 BA patients living with native livers between
ages 1 to 12. Interestingly, they found BMI and weight-for-age
z-scores inversely correlated with age [2]. In our study, boys
weight decreased between ages 2 to 6. While it is possible to
argue that lower relative weight might reflect poorer nutrition-
al status, patients in our study demonstrated unaltered height
gain and were of normal weight at the end of follow-up
suggesting adequate energy and protein intake to sustain
growth.
Postnatal corticosteroids have been used for prevention
and treatment of chronic lung disease in preterm infants
since 1980s [3]. In preterm infants, systemic corticoste-
roids have been shown to suppress growth [45, 48]. To
our best knowledge, there is only one prior study on the
effect of postoperative corticosteroid treatment on growth
of BA patients [1]. The role of postsurgical corticosteroids
remains polemic as previous studies from Asia [24, 32],
Europe [9], and the USA [14] have shown higher clear-
ance of jaundice rates for patients treated with corticoste-
roids, but this beneficial finding was not reciprocated in a
large North-American placebo-controlled trial [5]. The
START trial [1, 5] recently reported lower than norms z-
scores for length from portoenterostomy (69 patients) un-
til 24 months of age (35 patients) and for weight from
portoenterostomy (70 patients) until 18 months of age
(42 patients) for BA patients treated with post-surgical
corticosteroids (cumulative prednisolone dosage 116 mg/kg).
They also found significant difference between length z-scores
at 1, 2, and 3 months after portoenterostomy between patient
groups treated with corticosteroids or placebo (70 patients in
each group) [1]. In line with these findings, in our study, a
higher cumulative corticosteroid dosage (> 50 mg/kg) nega-
tively associated with growth by temporarily significantly
slowing height gain. In contrast to START trial, we did not
observe a long-term negative impact of corticosteroids on
weight or height; this is most likely due to the lower dosage
of corticosteroids used in our cohort. In our cohort, growth
accelerated between 3 and 6 months of age (median age at
portoenterostomy for all patients was 63 days) and height gain
was stable after that. Although in cholestatic liver disease in
early childhood there are multiple factors, such as changes in
growth hormone function [17, 21], inadequate resorption of
nutrition [35], and elevated energy consumption [18, 37] pos-
sibly affecting growth; the impact of corticosteroids was clear-
ly observable in our cohort of children with well-preserved
liver function.
Our study has some limitations. Because data were collect-
ed retrospectively, wewere unable to capture complete growth
data for all patients at all time points. Secondly, patients’ nu-
tritional status before PE and energy and protein intake during
follow-up could not be assessed reliably.
In conclusion, we found that BA patients surviving with
their native livers are shorter than their background population
at birth. Their height gain stays stable during early childhood.
High post-PE corticosteroid treatment dosage has a negative
impact on height gain and an observable positive impact on
weight gain compared to lower dosage, but these effects are of
short duration. However, as there are conflicting results regard-
ing the beneficial effects of postsurgical corticosteroid
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treatment for BA patients, it is wise to minimize the possible
risks of treatment and to avoid very high corticosteroid
dosages.
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